Drug Trial News

RSS

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented positive preliminary data from fully monitored study data for the entire study population of 80 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma.

8 Nov 2010

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

New malaria drug can save millions of lives: Study

A landmark trial showed that the replacement of the standard malaria drug Quinine with the newer drug Artesunate for children with severe malaria could save 100,000 lives a year. The World Health Organisation (WHO) recommended that artesunate derived from a Chinese plant called sweet wormwood, replace the four-century-old remedy of quinine for treating severe malaria in adults in 2006. Similar recommendations were not made for children with further trial results pending.

8 Nov 2010

AiCuris to present data on AIC316 anti-HSV drug at Antivirals Congress

AiCuris announced today the presentation of preclinical and Phase 1 data on AIC316 at the Antivirals Congress in Amsterdam, Netherlands, from 7th – 9th of November 2010. AIC316 is a novel anti-HSV drug currently in clinical phase 2 testing.

7 Nov 2010

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.

7 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

Researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco, and Pfizer Inc., have determined that two new compounds may be effective in treating both alcohol and nicotine dependence at the same time.

4 Nov 2010

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues and organs, today announced that OXY111A, its clinical stage candidate for the treatment of chronic heart failure and cancer, has been selected as one of Windover's "Top 10 Cardiovascular/Metabolic Projects to Watch."

4 Nov 2010

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that data from a phase I single-agent clinical trial of brentuximab vedotin (SGN-35) will be published in the November 4, 2010 issue of the New England Journal of Medicine.

4 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

World's most clinically advanced dengue vaccine candidate enters first phase 3 clinical study

Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate, entered its first phase 3 clinical study in Australia.

4 Nov 2010

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.

4 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases

Regado Biosciences, Inc., a private biopharmaceutical company leading the development of antithrombotic aptamers with matched active control agents, announced today that it has received funding from the United States government under the Qualifying Therapeutic Discovery Project (QTDP) grants program to advance the development of the company's three programs, REG1, REG2 and REG3.

4 Nov 2010

Coronado completes series of private financings

Coronado Biosciences, Inc., a privately held company engaged in innovative oncology drug development, announced completion of a series of private financings in 2010, resulting in aggregate gross proceeds to the Company of approximately $21.6 million.

4 Nov 2010

Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

Bolder BioTechnology, Inc. today announced that it has been awarded a total of $1.2 million in Qualifying Therapeutic Discovery Project Grants. Grants were awarded for qualified investments under the Qualifying Therapeutic Discovery Project Tax Credit Program, which authorized up to $1 billion in tax credits or grants to biopharmaceutical companies with 250 or fewer employees.

4 Nov 2010

Drug Trial News

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

New malaria drug can save millions of lives: Study

AiCuris to present data on AIC316 anti-HSV drug at Antivirals Congress

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

NWBT receives $490,000 in two grants under QTDP program

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

AVEO third quarter total collaboration revenues increase to $6.2 million

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Phase III study suggests CYCLOSET tablets improve glycemic control

World's most clinically advanced dengue vaccine candidate enters first phase 3 clinical study

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases

Coronado completes series of private financings

Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News